Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929870 | 1.00 | HSD17B10 (0.58) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19436611 | 0.89 | HPGD (0.70) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29929731 | 0.89 | HPGD (0.70) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19436802 | 0.88 | HSD17B10 (0.73) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19436691 | 0.85 | KDM4E (0.66) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19436729 | 0.81 | KDM4E (0.58) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19455107 | 0.81 | ALDH1A1 (0.47) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19455276 | 0.80 | HSD17B10 (0.61) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19436614 | 0.79 | KDM4E (0.60) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19436682 | 0.79 | KDM4E (0.60) | HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-12-07 | — | — | US | disclosed |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2021-03-02 | — | — | US | disclosed |
| US-20190330213-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-10-31 | — | — | US | disclosed |
| EP-3440080-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-9840510-B1 | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| WO-2017176960-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | HSD17B10 3819/4885KDM4E 1067/4885ALDH1A1 1260/4885 |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, PARK7, GAA | HSD17B10 4094/4885KDM4E 889/4885ALDH1A1 1084/4885 |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | HSD17B10 4115/4885KDM4E 690/4885ALDH1A1 1104/4885 |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | HSD17B10 4115/4885KDM4E 690/4885ALDH1A1 1104/4885 |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, GAA, PARK7 | HSD17B10 4037/4885KDM4E 1447/4885ALDH1A1 840/4885 |
| US-20190330213-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | HSD17B10 4115/4885KDM4E 690/4885ALDH1A1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.